Literature DB >> 23550670

Monetary costs of dementia in the United States.

Michael D Hurd1, Paco Martorell, Adeline Delavande, Kathleen J Mullen, Kenneth M Langa.   

Abstract

BACKGROUND: Dementia affects a large and growing number of older adults in the United States. The monetary costs attributable to dementia are likely to be similarly large and to continue to increase.
METHODS: In a subsample (856 persons) of the population in the Health and Retirement Study (HRS), a nationally representative longitudinal study of older adults, the diagnosis of dementia was determined with the use of a detailed in-home cognitive assessment that was 3 to 4 hours in duration and a review by an expert panel. We then imputed cognitive status to the full HRS sample (10,903 persons, 31,936 person-years) on the basis of measures of cognitive and functional status available for all HRS respondents, thereby identifying persons in the larger sample with a high probability of dementia. The market costs associated with care for persons with dementia were determined on the basis of self-reported out-of-pocket spending and the utilization of nursing home care; Medicare claims data were used to identify costs paid by Medicare. Hours of informal (unpaid) care were valued either as the cost of equivalent formal (paid) care or as the estimated wages forgone by informal caregivers.
RESULTS: The estimated prevalence of dementia among persons older than 70 years of age in the United States in 2010 was 14.7%. The yearly monetary cost per person that was attributable to dementia was either $56,290 (95% confidence interval [CI], $42,746 to $69,834) or $41,689 (95% CI, $31,017 to $52,362), depending on the method used to value informal care. These individual costs suggest that the total monetary cost of dementia in 2010 was between $157 billion and $215 billion. Medicare paid approximately $11 billion of this cost.
CONCLUSIONS: Dementia represents a substantial financial burden on society, one that is similar to the financial burden of heart disease and cancer. (Funded by the National Institute on Aging.).

Entities:  

Mesh:

Year:  2013        PMID: 23550670      PMCID: PMC3959992          DOI: 10.1056/NEJMsa1204629

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  14 in total

1.  Recent trends in state nursing home payment policies.

Authors:  David C Grabowski; Zhanlian Feng; Orna Intrator; Vincent Mor
Journal:  Health Aff (Millwood)       Date:  2004 Jan-Jun       Impact factor: 6.301

2.  2010 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2010-03       Impact factor: 21.566

3.  Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.

Authors:  R Brookmeyer; S Gray; C Kawas
Journal:  Am J Public Health       Date:  1998-09       Impact factor: 9.308

4.  Patterns of in-home care among elderly black and white Americans.

Authors:  T M Norgard; W L Rodgers
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  1997-05       Impact factor: 4.077

5.  National estimates of the quantity and cost of informal caregiving for the elderly with dementia.

Authors:  K M Langa; M E Chernew; M U Kabeto; A R Herzog; M B Ofstedal; R J Willis; R B Wallace; L M Mucha; W L Straus; A M Fendrick
Journal:  J Gen Intern Med       Date:  2001-11       Impact factor: 5.128

6.  A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): development and cross-validation.

Authors:  A F Jorm
Journal:  Psychol Med       Date:  1994-02       Impact factor: 7.723

7.  Sources of variability in estimates of the prevalence of Alzheimer's disease in the United States.

Authors:  Robert S Wilson; David R Weir; Sue E Leurgans; Denis A Evans; Liesi E Hebert; Kenneth M Langa; Brenda L Plassman; Brent J Small; David A Bennett
Journal:  Alzheimers Dement       Date:  2011-01       Impact factor: 21.566

8.  National estimates of the prevalence of Alzheimer's disease in the United States.

Authors:  Ron Brookmeyer; Denis A Evans; Liesi Hebert; Kenneth M Langa; Steven G Heeringa; Brenda L Plassman; Walter A Kukull
Journal:  Alzheimers Dement       Date:  2011-01       Impact factor: 21.566

9.  Dementia and out-of-pocket spending on health care services.

Authors:  Adeline Delavande; Michael D Hurd; Paco Martorell; Kenneth M Langa
Journal:  Alzheimers Dement       Date:  2012-11-13       Impact factor: 21.566

10.  Alzheimer disease in the US population: prevalence estimates using the 2000 census.

Authors:  Liesi E Hebert; Paul A Scherr; Julia L Bienias; David A Bennett; Denis A Evans
Journal:  Arch Neurol       Date:  2003-08
View more
  471 in total

1.  Parasympathetic and sympathetic nervous systems interactively predict change in cognitive functioning in midlife adults.

Authors:  Erik L Knight; Ryan J Giuliano; Sean W Shank; Megan M Clarke; David M Almeida
Journal:  Psychophysiology       Date:  2020-06-29       Impact factor: 4.016

2.  The Myth Regarding the High Cost of End-of-Life Care.

Authors:  Melissa D Aldridge; Amy S Kelley
Journal:  Am J Public Health       Date:  2015-10-15       Impact factor: 9.308

3.  Associations between informal care, disease, and risk factors: A Spanish country-wide population-based study.

Authors:  Luís González-de Paz; Jordi Real; Alicia Borrás-Santos; José M Martínez-Sánchez; Virginia Rodrigo-Baños; María Dolores Navarro-Rubio
Journal:  J Public Health Policy       Date:  2016-02-11       Impact factor: 2.222

4.  Health Services Utilization in Older Adults with Dementia Receiving Care Coordination: The MIND at Home Trial.

Authors:  Halima Amjad; Stephanie K Wong; David L Roth; Jin Huang; Amber Willink; Betty S Black; Deirdre Johnston; Peter V Rabins; Laura N Gitlin; Constantine G Lyketsos; Quincy M Samus
Journal:  Health Serv Res       Date:  2017-01-12       Impact factor: 3.402

5.  Improving Dementia Long-Term Care: A Policy Blueprint.

Authors:  Regina A Shih; Thomas W Concannon; Jodi L Liu; Esther M Friedman
Journal:  Rand Health Q       Date:  2014-06-01

6.  Apolipoproteins and HDL cholesterol do not associate with the risk of future dementia and Alzheimer's disease: the National Finnish population study (FINRISK).

Authors:  Juho Tynkkynen; Jussi A Hernesniemi; Tiina Laatikainen; Aki S Havulinna; Jouko Sundvall; Jaana Leiviskä; Perttu Salo; Veikko Salomaa
Journal:  Age (Dordr)       Date:  2016-09-23

7.  Use of FDA approved medications for Alzheimer's disease in mild dementia is associated with reduced informal costs of care.

Authors:  Stephanie Behrens; Gail B Rattinger; Sarah Schwartz; Joshua Matyi; Chelsea Sanders; M Scott DeBerard; Constantine G Lyketsos; JoAnn T Tschanz
Journal:  Int Psychogeriatr       Date:  2018-03-21       Impact factor: 3.878

Review 8.  The impact of cerebrovascular aging on vascular cognitive impairment and dementia.

Authors:  Tuo Yang; Yang Sun; Zhengyu Lu; Rehana K Leak; Feng Zhang
Journal:  Ageing Res Rev       Date:  2016-09-28       Impact factor: 10.895

Review 9.  Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward.

Authors:  David Hsu; Gad A Marshall
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

10.  Reproducibility of brain MRS in older healthy adults at 7T.

Authors:  S Andrea Wijtenburg; Laura M Rowland; Georg Oeltzschner; Peter B Barker; Clifford I Workman; Gwenn S Smith
Journal:  NMR Biomed       Date:  2018-11-29       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.